What will Johnson & Johnson say during their next earnings call?
The market resolves based on specific topics mentioned by Johnson & Johnson during their next earnings call.
Kalshi$131 traded 24hEnds Mar 31, 2027Outcomes
Yes pays $1 if it happens · best price highlighted
| Outcome | Chance | 24h | Last 24h | Kalshi |
|---|---|---|---|---|
| Litigation | 82% | — | 86¢ | |
| Darzalex Faspro | 65% | — | 65¢ | |
| AI / Artificial Intelligence | 48% | — | 52¢ | |
| Ottava | 90% | — | 90¢ | |
| Rybrevant | 89% | — | 90¢ | |
| Procedure | 89% | — | 90¢ | |
| China | 88% | — | 90¢ | |
| Tariff | 82% | — | 87¢ | |
| Halda Therapeutics | 56% | — | 61¢ | |
| Caplyta | 53% | — | 90¢ | |
| Tecvayli | 48% | — | 90¢ | |
| Firefly Bio | 47% | — | 89¢ | |
| Nipocalimab / Lupus | 34% | — | 39¢ | |
| Administration | 31% | — | 36¢ | |
| Gene Therapy | 9% | — | 13¢ | |
| Vaccine | 6% | — | 11¢ |
Litigation
82%
—Yes price on Kalshi, last 2 weeks
Discussion
Posts and calls about this event
Live room
Connecting…Loading…
Sign in to chat in the room.